Reevaluation of solubility of tolbutamide and polymorphic transformation from Form I to unknown crystal form
Thermodynamic stability order of tolbutamide between polymorphs was evaluated using calorimetry and spectroscopic analysis. The heat of solution (Δ H) of Forms I–III measurements were carried out in dimethylsulfoxide between 298.2 K and 319.2 K. It was found that the Δ H of Forms II and III was incr...
Gespeichert in:
Veröffentlicht in: | International journal of pharmaceutics 2009-03, Vol.369 (1), p.12-18 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 18 |
---|---|
container_issue | 1 |
container_start_page | 12 |
container_title | International journal of pharmaceutics |
container_volume | 369 |
creator | Hasegawa, Gen Komasaka, Takao Bando, Rui Yoshihashi, Yasuo Yonemochi, Etsuo Fujii, Kotaro Uekusa, Hidehiro Terada, Katsuhide |
description | Thermodynamic stability order of tolbutamide between polymorphs was evaluated using calorimetry and spectroscopic analysis. The heat of solution (Δ
H) of Forms I–III measurements were carried out in dimethylsulfoxide between 298.2
K and 319.2
K. It was found that the Δ
H of Forms II and III was increased nearly parallel with a temperature rise. However, change of the Δ
H of Form I with a temperature rise was not in correspondence with that of other forms. Solubility data confirmed the change in Δ
H of Form I around 308.2
K. XRD–DSC measurement of Form I detected a polymorphic transformation (Form I
L
→
unknown form) at 311
K. Obtained data suggested that the new crystal form (Form I
H) would exist above 311
K, and the order of thermodynamic stability was “Form III
<
Form I
L
<
Form II” below the transition temperature, on the other hand, the order was changed in “Form I
L and Form I
H
<
Form III
<
Form II” above the transition temperature. The crystal structure of Form I
H was determined by measurement of PXRD pattern on BL19B2 at SPring-8, and the change in the solid-state NMR spectrum confirmed the transformation of the crystal structure of Form I
L. |
doi_str_mv | 10.1016/j.ijpharm.2008.10.018 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66985510</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378517308007291</els_id><sourcerecordid>66985510</sourcerecordid><originalsourceid>FETCH-LOGICAL-c503t-c82a2c2c8882493eaa0e82c82c559e95bbe03a703c220a912b432d63d14f33c43</originalsourceid><addsrcrecordid>eNqFkM1q3DAURkVpaKZpH6FFm3bniX4sWV6FEpo2ECiEZC1k-ZpoKluuJKfM20dmTLrsSnyX811dDkKfKNlTQuXlYe8O85OJ454RospsT6h6g3ZUNbzidSPfoh3hjaoEbfg5ep_SgRAiGeXv0DltCZMNZzvk7wGejV9MdmHCYcAp-KVz3uXjmnLw3ZLN6HrAZurxHPxxDHF-chbnaKY0hDieukMMI74pEd-WGl6m31P4O2Ebjykbj1fwAzobjE_wcXsv0OPN94frn9Xdrx-319_uKisIz5VVzDDLrFKK1S0HYwioEpkVooVWdB0QbhrCLWPEtJR1NWe95D2tB85tzS_Q19PeOYY_C6SsR5cseG8mCEvSUrZKCEoKKE6gjSGlCIOeoxtNPGpK9KpZH_SmWa-a13HRXHqftw-WboT-X2vzWoAvG2CSNX4oqqxLrxyjTEom1kuvThwUHc8Ook7WwWShdxFs1n1w_znlBREXn8c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66985510</pqid></control><display><type>article</type><title>Reevaluation of solubility of tolbutamide and polymorphic transformation from Form I to unknown crystal form</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Hasegawa, Gen ; Komasaka, Takao ; Bando, Rui ; Yoshihashi, Yasuo ; Yonemochi, Etsuo ; Fujii, Kotaro ; Uekusa, Hidehiro ; Terada, Katsuhide</creator><creatorcontrib>Hasegawa, Gen ; Komasaka, Takao ; Bando, Rui ; Yoshihashi, Yasuo ; Yonemochi, Etsuo ; Fujii, Kotaro ; Uekusa, Hidehiro ; Terada, Katsuhide</creatorcontrib><description>Thermodynamic stability order of tolbutamide between polymorphs was evaluated using calorimetry and spectroscopic analysis. The heat of solution (Δ
H) of Forms I–III measurements were carried out in dimethylsulfoxide between 298.2
K and 319.2
K. It was found that the Δ
H of Forms II and III was increased nearly parallel with a temperature rise. However, change of the Δ
H of Form I with a temperature rise was not in correspondence with that of other forms. Solubility data confirmed the change in Δ
H of Form I around 308.2
K. XRD–DSC measurement of Form I detected a polymorphic transformation (Form I
L
→
unknown form) at 311
K. Obtained data suggested that the new crystal form (Form I
H) would exist above 311
K, and the order of thermodynamic stability was “Form III
<
Form I
L
<
Form II” below the transition temperature, on the other hand, the order was changed in “Form I
L and Form I
H
<
Form III
<
Form II” above the transition temperature. The crystal structure of Form I
H was determined by measurement of PXRD pattern on BL19B2 at SPring-8, and the change in the solid-state NMR spectrum confirmed the transformation of the crystal structure of Form I
L.</description><identifier>ISSN: 0378-5173</identifier><identifier>EISSN: 1873-3476</identifier><identifier>DOI: 10.1016/j.ijpharm.2008.10.018</identifier><identifier>PMID: 19026732</identifier><identifier>CODEN: IJPHDE</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Biological and medical sciences ; Calorimetry, Differential Scanning ; Crystallization ; Drug Stability ; General pharmacology ; Hypoglycemic Agents - chemistry ; Medical sciences ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Polymorphic transformation ; Solid-state NMR ; Solubility ; Structure determination from PXRD data ; Temperature ; Thermodynamics ; Tolbutamide ; Tolbutamide - chemistry ; X-Ray Diffraction</subject><ispartof>International journal of pharmaceutics, 2009-03, Vol.369 (1), p.12-18</ispartof><rights>2008 Elsevier B.V.</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c503t-c82a2c2c8882493eaa0e82c82c559e95bbe03a703c220a912b432d63d14f33c43</citedby><cites>FETCH-LOGICAL-c503t-c82a2c2c8882493eaa0e82c82c559e95bbe03a703c220a912b432d63d14f33c43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijpharm.2008.10.018$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21266254$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19026732$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hasegawa, Gen</creatorcontrib><creatorcontrib>Komasaka, Takao</creatorcontrib><creatorcontrib>Bando, Rui</creatorcontrib><creatorcontrib>Yoshihashi, Yasuo</creatorcontrib><creatorcontrib>Yonemochi, Etsuo</creatorcontrib><creatorcontrib>Fujii, Kotaro</creatorcontrib><creatorcontrib>Uekusa, Hidehiro</creatorcontrib><creatorcontrib>Terada, Katsuhide</creatorcontrib><title>Reevaluation of solubility of tolbutamide and polymorphic transformation from Form I to unknown crystal form</title><title>International journal of pharmaceutics</title><addtitle>Int J Pharm</addtitle><description>Thermodynamic stability order of tolbutamide between polymorphs was evaluated using calorimetry and spectroscopic analysis. The heat of solution (Δ
H) of Forms I–III measurements were carried out in dimethylsulfoxide between 298.2
K and 319.2
K. It was found that the Δ
H of Forms II and III was increased nearly parallel with a temperature rise. However, change of the Δ
H of Form I with a temperature rise was not in correspondence with that of other forms. Solubility data confirmed the change in Δ
H of Form I around 308.2
K. XRD–DSC measurement of Form I detected a polymorphic transformation (Form I
L
→
unknown form) at 311
K. Obtained data suggested that the new crystal form (Form I
H) would exist above 311
K, and the order of thermodynamic stability was “Form III
<
Form I
L
<
Form II” below the transition temperature, on the other hand, the order was changed in “Form I
L and Form I
H
<
Form III
<
Form II” above the transition temperature. The crystal structure of Form I
H was determined by measurement of PXRD pattern on BL19B2 at SPring-8, and the change in the solid-state NMR spectrum confirmed the transformation of the crystal structure of Form I
L.</description><subject>Biological and medical sciences</subject><subject>Calorimetry, Differential Scanning</subject><subject>Crystallization</subject><subject>Drug Stability</subject><subject>General pharmacology</subject><subject>Hypoglycemic Agents - chemistry</subject><subject>Medical sciences</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Polymorphic transformation</subject><subject>Solid-state NMR</subject><subject>Solubility</subject><subject>Structure determination from PXRD data</subject><subject>Temperature</subject><subject>Thermodynamics</subject><subject>Tolbutamide</subject><subject>Tolbutamide - chemistry</subject><subject>X-Ray Diffraction</subject><issn>0378-5173</issn><issn>1873-3476</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkM1q3DAURkVpaKZpH6FFm3bniX4sWV6FEpo2ECiEZC1k-ZpoKluuJKfM20dmTLrsSnyX811dDkKfKNlTQuXlYe8O85OJ454RospsT6h6g3ZUNbzidSPfoh3hjaoEbfg5ep_SgRAiGeXv0DltCZMNZzvk7wGejV9MdmHCYcAp-KVz3uXjmnLw3ZLN6HrAZurxHPxxDHF-chbnaKY0hDieukMMI74pEd-WGl6m31P4O2Ebjykbj1fwAzobjE_wcXsv0OPN94frn9Xdrx-319_uKisIz5VVzDDLrFKK1S0HYwioEpkVooVWdB0QbhrCLWPEtJR1NWe95D2tB85tzS_Q19PeOYY_C6SsR5cseG8mCEvSUrZKCEoKKE6gjSGlCIOeoxtNPGpK9KpZH_SmWa-a13HRXHqftw-WboT-X2vzWoAvG2CSNX4oqqxLrxyjTEom1kuvThwUHc8Ook7WwWShdxFs1n1w_znlBREXn8c</recordid><startdate>20090318</startdate><enddate>20090318</enddate><creator>Hasegawa, Gen</creator><creator>Komasaka, Takao</creator><creator>Bando, Rui</creator><creator>Yoshihashi, Yasuo</creator><creator>Yonemochi, Etsuo</creator><creator>Fujii, Kotaro</creator><creator>Uekusa, Hidehiro</creator><creator>Terada, Katsuhide</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20090318</creationdate><title>Reevaluation of solubility of tolbutamide and polymorphic transformation from Form I to unknown crystal form</title><author>Hasegawa, Gen ; Komasaka, Takao ; Bando, Rui ; Yoshihashi, Yasuo ; Yonemochi, Etsuo ; Fujii, Kotaro ; Uekusa, Hidehiro ; Terada, Katsuhide</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c503t-c82a2c2c8882493eaa0e82c82c559e95bbe03a703c220a912b432d63d14f33c43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Biological and medical sciences</topic><topic>Calorimetry, Differential Scanning</topic><topic>Crystallization</topic><topic>Drug Stability</topic><topic>General pharmacology</topic><topic>Hypoglycemic Agents - chemistry</topic><topic>Medical sciences</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Polymorphic transformation</topic><topic>Solid-state NMR</topic><topic>Solubility</topic><topic>Structure determination from PXRD data</topic><topic>Temperature</topic><topic>Thermodynamics</topic><topic>Tolbutamide</topic><topic>Tolbutamide - chemistry</topic><topic>X-Ray Diffraction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hasegawa, Gen</creatorcontrib><creatorcontrib>Komasaka, Takao</creatorcontrib><creatorcontrib>Bando, Rui</creatorcontrib><creatorcontrib>Yoshihashi, Yasuo</creatorcontrib><creatorcontrib>Yonemochi, Etsuo</creatorcontrib><creatorcontrib>Fujii, Kotaro</creatorcontrib><creatorcontrib>Uekusa, Hidehiro</creatorcontrib><creatorcontrib>Terada, Katsuhide</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hasegawa, Gen</au><au>Komasaka, Takao</au><au>Bando, Rui</au><au>Yoshihashi, Yasuo</au><au>Yonemochi, Etsuo</au><au>Fujii, Kotaro</au><au>Uekusa, Hidehiro</au><au>Terada, Katsuhide</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reevaluation of solubility of tolbutamide and polymorphic transformation from Form I to unknown crystal form</atitle><jtitle>International journal of pharmaceutics</jtitle><addtitle>Int J Pharm</addtitle><date>2009-03-18</date><risdate>2009</risdate><volume>369</volume><issue>1</issue><spage>12</spage><epage>18</epage><pages>12-18</pages><issn>0378-5173</issn><eissn>1873-3476</eissn><coden>IJPHDE</coden><abstract>Thermodynamic stability order of tolbutamide between polymorphs was evaluated using calorimetry and spectroscopic analysis. The heat of solution (Δ
H) of Forms I–III measurements were carried out in dimethylsulfoxide between 298.2
K and 319.2
K. It was found that the Δ
H of Forms II and III was increased nearly parallel with a temperature rise. However, change of the Δ
H of Form I with a temperature rise was not in correspondence with that of other forms. Solubility data confirmed the change in Δ
H of Form I around 308.2
K. XRD–DSC measurement of Form I detected a polymorphic transformation (Form I
L
→
unknown form) at 311
K. Obtained data suggested that the new crystal form (Form I
H) would exist above 311
K, and the order of thermodynamic stability was “Form III
<
Form I
L
<
Form II” below the transition temperature, on the other hand, the order was changed in “Form I
L and Form I
H
<
Form III
<
Form II” above the transition temperature. The crystal structure of Form I
H was determined by measurement of PXRD pattern on BL19B2 at SPring-8, and the change in the solid-state NMR spectrum confirmed the transformation of the crystal structure of Form I
L.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>19026732</pmid><doi>10.1016/j.ijpharm.2008.10.018</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0378-5173 |
ispartof | International journal of pharmaceutics, 2009-03, Vol.369 (1), p.12-18 |
issn | 0378-5173 1873-3476 |
language | eng |
recordid | cdi_proquest_miscellaneous_66985510 |
source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
subjects | Biological and medical sciences Calorimetry, Differential Scanning Crystallization Drug Stability General pharmacology Hypoglycemic Agents - chemistry Medical sciences Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments Polymorphic transformation Solid-state NMR Solubility Structure determination from PXRD data Temperature Thermodynamics Tolbutamide Tolbutamide - chemistry X-Ray Diffraction |
title | Reevaluation of solubility of tolbutamide and polymorphic transformation from Form I to unknown crystal form |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T19%3A06%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reevaluation%20of%20solubility%20of%20tolbutamide%20and%20polymorphic%20transformation%20from%20Form%20I%20to%20unknown%20crystal%20form&rft.jtitle=International%20journal%20of%20pharmaceutics&rft.au=Hasegawa,%20Gen&rft.date=2009-03-18&rft.volume=369&rft.issue=1&rft.spage=12&rft.epage=18&rft.pages=12-18&rft.issn=0378-5173&rft.eissn=1873-3476&rft.coden=IJPHDE&rft_id=info:doi/10.1016/j.ijpharm.2008.10.018&rft_dat=%3Cproquest_cross%3E66985510%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66985510&rft_id=info:pmid/19026732&rft_els_id=S0378517308007291&rfr_iscdi=true |